Prognostic Factors and Overall Survival in Nasopharyngeal Carcinoma: A Ten-Year Single-Center Experience

Abstract

Objective: Nasopharyngeal carcinoma (NPC) is a malignancy originating from the epithelial layer of the nasopharynx. In our study, we aimed to investigate the factors affecting treatment response and survival in patients diagnosed with NPC. Methods: A retrospective study was conducted on 76 patients aged ≥18 years with a pathological diagnosis of NPC who presented to the Oncology Clinic of Dicle University Faculty of Medicine between January 2010 and May 2020. General characteristics of the patients and their effects on overall survival were evaluated. Results: The mean age of the patients was 46. There were 39 patients (51.3%) under 50 years and 37 patients (48.7%) ≥50 years. 18 were female (23.7%) and 58 were male (76.3%). The mean body mass index (BMI) was 24.1±5.2. 39 patients (51.3%) were smokers, and 37 patients (48.7%) were not. At the time of diagnosis, 11 patients (14.5%) were TNM Stage 2, 39 patients (51.3%) were Stage 3, and 26 patients (34.2%) were Stage 4. According to the WHO 2005 histological classification, there were 30 patients (39.5%) in Type 2A and 40 patients (52.6%) in Type 2B. There were no patients with Type 1 or Type 3 tumors. Other tumor types were detected in 6 patients (7.9%). In the survival analysis, 25 patients (32.9%) were deceased and 51 (67.1%) were alive. Kaplan-Meier analysis revealed a mean survival time of 108 months (95% CI = 88-128). Multivariate Cox regression analysis showed that advanced stage of TNM at diagnosis, low BMI, and high serum lactate dehydrogenase (LDH) levels negatively impacted survival (p=0.017, p=0.04, p=0.04, respectively). Conclusion: In NPC, the patient's TNM stage at diagnosis, BMI level, and serum LDH level may be independent prognostic risk factors.

Keywords

• Nasopharyngeal carcinoma
• prognostic factor
• overall survival

Nazofaringeal Karsinomda Prognostik Faktörler ve Genel Sağkalım: Tek Merkezli 10 Yıllık Deneyim

Abstract

Amaç: Nazofarengeal karsinom (NFK), nazofarenksin epitel tabakasından kaynaklanan bir malignitedir. Çalışmamızda, NFK tanılı hastalarda tedavi yanıtı ve sağkalımı etkileyen faktörleri araştırmayı amaçladık. Yöntemler: Ocak 2010-Mayıs 2020 tarihleri arasında Dicle Üniversitesi Onkoloji polikliniğine başvuran ≥18 yaş ve patolojik tanısı NFK olan 76 hasta retrospektif olarak incelendi. Hastaların genel özellikleri ve genel sağkalım üzerine etkileri değerlendirildi. Bulgular: Hastaların ortalama yaşı 46 idi. <50 yaş 39 (%51,3), ≥50 yaş 37 hasta (%48,7) vardı. 18’i kadın (%23,7), 58’i erkekti (%76,3). Ortalama beden kitle indeksi (BMI) 24.1±5.2 idi. 39 hastada (%51,3) sigara içimi vardı, 37 hastada (%48,7) yoktu. Tanı anında 11 hasta (%14,5) TNM Evre 2, 39 hasta (%51,3) Evre 3 ve 26 hasta (%34,2) Evre 4 idi. WHO 2005 histolojik sınıflamasına göre Tip 2A’da 30 (%39,5) ve Tip 2B’de 40 (%52,6) hasta vardı. Tip 1 ve Tip 3 hasta yoktu. 6 hastada (%7,9) diğer tümör tipleri tespit edildi. Sağkalım analizinde, hastaların 25’i (%32,9) ölü, 51’i (%67,1) hayattaydı. Kaplan-Meier analizi sonucu ortalama sağkalım süresi 108 ay (%95 CI= 88-128) olarak bulundu. Multivariate Cox regression analizinde tanı anındaki TNM ileri evrenin, BMI düşüklüğünün ve serum laktat dehidrogenaz (LDH) düzeyi yüksekliğinin sağkalımı olumsuz etkilediği bulundu (sırasıyla, p=0.017, p=0.04, p=0.04). Sonuç: NFK’de hastanın tanı anındaki TNM evresi, BMI düzeyi ve serum LDH düzeyi bağımsız prognostik risk faktörü olabilir.

Keywords

• Nazofarengeal karsinom
• prognostik faktör
• overall survival.

References

1. 1.Gunderson L, Teper J. Clinical Radiation Oncology.Second Edition. Churchill Livingstone, Philadelphia,ch 31, 2007, pp 705-26.
2. 2.Liu MT, Hsieh CY, Chang TH, Lin JP, Huang CC,Wang AY. Prognostic factors affecting the outcomeof nasopharyngeal carcinoma. Jpn J Clin Oncol. 2003Oct;33(10):501-8.
3. 3.Arthur C, Ruan H, Wang X, et al. RetrospectiveAnalysis of 5-Year Survival Rate of NasopharyngealCarcinoma: Correlation with Clinical Features andPrognosis. J Cancer Res Therap Oncol. 2019, 7: 1-16.
4. 4.Chua MLK, Wee JTS, Hui EP, Chan ATC.Nasopharyngeal carcinoma. Lancet. 2016 Mar5;387(10022):1012-24.
5. 5.Li XY, Chen QY, Sun XS, et al. Ten-year outcomes ofsurvival and toxicity for a phase III randomised trialof concurrent chemoradiotherapy versusradiotherapy alone in stage II nasopharyngealcarcinoma. Eur J Cancer. 2019 Mar;110:24-31.
6. 6. Blanchard P, Lee A, Marguet S, et al. Chemotherapyand radiotherapy in nasopharyngeal carcinoma: anupdate of the MAC-NPC meta-analysis. Lancet Oncol.2015 Jun;16(6):645-55.
7. 7.Rodriguez-Galindo C, Krailo MD, Krasin MJ, et al.Treatment of Childhood Nasopharyngeal Carcinomawith Induction Chemotherapy and ConcurrentChemoradiotherapy: Results of the Children'sOncology Group ARAR0331 Study. J Clin Oncol. 2019Dec 10;37(35):3369-76.
8. 8.Siti-Azrin AH, Norsa'adah B, Naing NN. Prognosticfactors of nasopharyngeal carcinoma patients in atertiary referral hospital: a retrospective cohortstudy. BMC Res Notes. 2017 Dec 6;10(1):705.

9. 9.Bray F, Ferlay J, Laversanne M, et al. CancerIncidence in Five Continents: Inclusion criteria,highlights from Volume X and the global status ofcancer registration. Int J Cancer. 2015 Nov1;137(9):2060-71.
10. 10.Perez CA, Devineni VR, Marcial-Vega V, Marks JE,Simpson JR, Kucik N. Carcinoma of the nasopharynx: Factors affecting prognosis. Int J Radiat Oncol Biol Phys 1992;23:271–80.
11. 11.Possenti I, Martini A, Bagnardi V, et al.Association between cigarette smoking andnasopharyngeal cancer risk: a meta-analysis.Rhinology. 2025 Feb 1;63(1):13-21.
12. 12.Dhanapal R, Saraswathi T, Govind RN. Cancercachexia. J Oral Maxillofac Pathol 2011;15(3):257–60.
13. 13.Van Cutsem E, Arends J. The causes andconsequences of cancerassociated malnutrition. EurJ Oncol Nurs. 2005;9(Suppl 2):S51–63.
14. 14.Huang PY, Wang CT, Cao KJ, et al. Pretreatmentbody mass index as an independent prognosticfactor in patients with locoregionally advancednasopharyngeal carcinoma treated withchemoradiotherapy: findings from a randomisedtrial. Eur J Cancer. 2013;49(8):1923–31.
15. 15.Soeters PB, Wolfe RR, Shenkin A.Hypoalbuminemia: Pathogenesis and ClinicalSignificance. JPEN J Parenter Enteral Nutr. 2019Feb;43(2):181-93.
16. 16.Yang H, Wang K, Liang Z, et al. Prognostic role ofpre-treatment serum albumin in patients withnasopharyngeal carcinoma: A meta-analysis andsystematic review. Clin Otolaryngol. 2020Mar;45(2):167-76.
17. 17.Vaupel P, Mayer A, Hockel M. Tumor hypoxia andmalignant progression. Methods Enzymol. 2004;381: 335–54.
18. 18.Schäfer U, Micke O, Müller SB, Schüller P, WillichN.Hemoglobin as an independent prognostic factorin the radiotherapy of head and neck tumors.Strahlenther Onkol. 2003 Aug;179(8):527-34.
19. 19.Li J, Chen S, Peng S, et al. Prognostic nomogramfor patients with Nasopharyngeal Carcinomaincorporating hematological biomarkers andclinical characteristics. Int J Biol Sci. 2018 Apr5;14(5):549-56.
20. 20.Wei Z, Zeng X, Xu J, Duan X, Xie Y. Prognosticvalue of pretreatment serum levels of lactatedehydrogenase in nonmetastatic nasopharyngealcarcinoma: single-site analysis of 601 patients in ahighly endemic area. Onco Targets Ther. 2014 May15;7:739-49.
21. 21.Li G, Gao J, Tao YL, et al. Increased pretreatmentlevels of serum LDH and ALP as poor prognosticfactors for nasopharyngeal carcinoma. Chin J Cancer.2012 Apr;31(4):197-206.
22. 22.Zhou GQ, Tang LL, Mao YP, et al. Baseline serumlactate dehydrogenase levels for patients treatedwith intensity-modulated radiotherapy fornasopharyngeal carcinoma: a predictor of poorprognosis and subsequent liver metastasis. Int JRadiat Oncol Biol Phys. 2012 Mar 1;82(3):e359-65.
23. 23.Wan XB, Wei L, Li H, et al. High pretreatmentserum lactate dehydrogenase level correlates withdisease relapse and predicts an inferior outcome inlocally advanced nasopharyngeal carcinoma. Eur JCancer. 2013 Jul;49(10):2356-64.
24. 24.Guo L. F., Hong J. G., Wang R. J., Chen G. P., Wu S.G.(2024). Nasopharyngeal carcinoma survival byhistology in endemic and non-endemic areas. Annalsof Medicine, 56(1).
25. 25.Sali S, Abakay CD, Sali M, et al. Prognostic Valueof Histological Subtypes and Clinical Factors in Non-Endemic Nasopharyngeal Carcinoma: ARetrospective Cohort Study. Medicina. 2025;61(12):2207.
26. 26.Sinha S, Winters R, Gajra A. NasopharyngealCancer. 2024 Feb 3. In: StatPearls [Internet].
27. 27.Jen CW, Tsai YC, Wu JS, et al. Prognosticclassification for patients with nasopharyngealcarcinoma based on American Joint Committee oncancer staging system T and N categories. TherRadiol Oncol. 2020;4:2.